Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer

2019 ◽  
Vol 67 (6) ◽  
pp. 537-543
Author(s):  
Tomoshi Tsuchiya ◽  
Keitaro Matsumoto ◽  
Takuro Miyazaki ◽  
Hiroyuki Yamaguchi ◽  
Takuya Yamazaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Small Cell ◽  
Stage Ii ◽  
Small Cell Lung

scholarly journals 10P Impact of the number of metastatic lymph nodes on survival in pathological stage II-N1 non-small cell lung cancer

2021 ◽  
Vol 16 (4) ◽  
pp. S703
Author(s):  
J. de Ruiter ◽  
A. de Langen ◽  
K. Monkhorst ◽  
A. Veenhof ◽  
H. Klomp ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Nodes ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Ii ◽  
Pathological Stage ◽  
Small Cell Lung ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

186 A phase I/II trial of concurrent chemo-radiation with dose-escalated radiotherapy in patients with stage II or stage III non-small cell lung cancer

Lung Cancer ◽  
2013 ◽  
Vol 79 ◽  
pp. S64-S65
Author(s):  
D.B. Landau ◽  
E. Miles ◽  
M. Illsley ◽  
V. Laurence ◽  
S. Hughes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Ii ◽  
Stage Iii ◽  
Small Cell Lung

Treatment of Stage II Non-small Cell Lung Cancer*

CHEST Journal ◽  
2003 ◽  
Vol 123 (1) ◽  
pp. 188S-201S ◽  
Author(s):  
Walter J. Scott ◽  
John Howington ◽  
Benjamin Movsas
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Ii ◽  
Small Cell Lung

Uptake and outcomes of adjuvant durvalumab following concurrent chemoradiotherapy in unresected stage 3 non-small-cell lung cancer

Lung Cancer ◽  
2021 ◽  
Vol 156 ◽  
pp. S41
Author(s):  
Holly Mason ◽  
Pooja Jain ◽  
Fei Sun ◽  
Mark Teo ◽  
Kevin Franks ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Small Cell ◽  
Small Cell Lung

Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 8501-8501
Author(s):  
Hirohito Tada ◽  
Tetsuya Mitsudomi ◽  
Takeharu Yamanaka ◽  
Kenji Sugio ◽  
Masahiro Tsuboi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Disease Free Survival ◽  
Small Cell ◽  
Stage Ii ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Egfr Mutated

8501 Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor is a standard of care for EGFR mutation-positive, untreated metastatic non-small cell lung cancer (NSCLC). However, the efficacy and safety of adjuvant gefitinib for patients with completely resected lung cancer harboring EGFR mutation over cisplatin-based adjuvant chemotherapy were not known in 2011 when this study was initiated. Methods: From September 2011 to December 2015, we randomly assigned 234 patients with completely resected, EGFR mutation-positive (exon 19 deletion or L858R), stage II–III NSCLC to receive either gefitinib (250 mg, once daily) for 24 months or cisplatin (80 mg/m2 on day 1) plus vinorelbine (25 mg/m2 on days 1 and 8) (cis/vin) every 3 weeks for four cycles. The primary endpoint was disease-free survival (DFS) according to a central review in the intent-to-treat (ITT) population. Results: Two patients in the gefitinib arm withdrew consent and were excluded from the ITT population. No treatment-related deaths were seen in the gefitinib arm, but three treatment-related deaths were reported in the cis/vin arm. Median duration of follow-up was 71 months. Median DFS was numerically longer in the gefitinib arm (36 months) than in the cis/vin arm (25.2 months). However, Kaplan-Meier curves began to overlap around 5 years after surgery, and no significant difference in DFS was seen, with a hazard ratio (HR) of 0.92 (95% confidence interval (CI), 0.67–1.28; P = 0.63). Overall survival was also not significantly different (median not reached in either arm). Five-year survival rates for gefitinib and cis/vin arms were 78.0% and 74.6%, respectively, with an HR for death of 1.03; 95%CI, 0.65–1.65; P = 0.89. Exploratory subset analysis revealed that patients ³70 years old in the gefitinib arm (n = 19/27 with G to cis/vin) survived longer than those in the cis/vin arm (HR 0.31; 95%CI, 0.10–0.98; P = 0.046). Conclusions: Adjuvant gefitinib appeared to prevent early relapse, but did not significantly prolong DFS or OS in patients with completely resected stage II–III, EGFR-mutated NSCLC. The apparent non-inferiority of DFS/OS may justify the use of adjuvant gefitinib in selected subset of patients, especially those deemed unsuitable for cis/vin adjuvant therapy. Clinical trial information: UMIN000006252.

Sign in / Sign up

Export Citation Format

Share Document